mRNA Vaccine to Prevent EBV After Transplant
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests an mRNA vaccine that may help prevent Epstein-Barr virus (EBV) infections and related diseases after a stem cell transplant. It is for people who have received or will receive a donor stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 14 years old.
- You have had or are about to have a stem cell transplant from a donor (allogeneic transplant).
- You have no history of severe allergic reaction to vaccines.
- You do not currently have active acute graft-versus-host disease (aGVHD).
- Your heart, liver, and kidney function are not severely impaired.
- You have not had a fever above 100.4°F in the 3 days before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
This trial tests an mRNA vaccine to treat advanced cancers linked to the Epstein-Barr virus, such as nasopharyngeal cancer, NK/T-cell lymphoma, and stomach cancer. The vaccine teaches your immune system to fight the virus and the cancer.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This trial tests giving special immune cells (EBV-specific T cells) from the donor to prevent Epstein-Barr virus (EBV) infections after a stem cell transplant. It may help people who have a high risk of EBV reactivation.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
Hear when a new Patients After Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.